Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Center of Excellence in Osteoarthritis and Musculoskeleton, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
J Med Virol. 2023 May;95(5):e28758. doi: 10.1002/jmv.28758.
To compare the reactogenicity and immunogenicity between the two-dose mRNA COVID-19 vaccine regimen and one or two doses of inactivated vaccine followed by an mRNA vaccine regimen in healthy children between 5 and 11 years of age, a prospective cohort study was performed at King Chulalongkorn Memorial Hospital in Thailand between March to June 2022. Healthy children between 5 and 11 years of age were enrolled and received the two-dose mRNA COVID-19 vaccine (BNT162b2) regimen or the inactivated (CoronaVac) vaccine followed by the BNT162b2 vaccine regimen. In addition, healthy children who received two doses of BBIBP-CorV between 1 and 3 months prior were enrolled to receive a heterologous BNT162b2 as a third dose (booster). Reactogenicity was assessed by a self-reported online questionnaire. Immunogenicity analysis was performed to determine binding antibodies to wild-type SARS-CoV-2. Neutralizing antibodies to Omicron variants (BA.2 and BA.5) were tested using the focus reduction neutralization test. Overall, 166 eligible children were enrolled. Local and systemic adverse events which occurred within 7 days after vaccination were mild to moderate and well-tolerated. The two-dose BNT162b2, CoronaVac followed by BNT162b2, and two-dose BBIBP-CorV followed by BNT162b2 groups elicited similar levels of anti-receptor-binding domain (RBD) IgG. However, the two-dose BNT162b2 and two-dose BBIBP-CorV followed by BNT162b2 groups elicited higher neutralizing activities against the Omicron BA.2 and BA.5 variant than the CoronaVac followed by BNT162b2 group. The CoronaVac followed by BNT162b2 group elicited low neutralizing activities against the Omicron BA.2 and BA.5 variant. A third dose (booster) mRNA vaccine should be prioritized for this group.
为了比较 5 至 11 岁健康儿童中两剂 mRNA COVID-19 疫苗方案与一剂或两剂灭活疫苗后再接种 mRNA 疫苗方案的反应原性和免疫原性，泰国朱拉隆功国王纪念医院于 2022 年 3 月至 6 月开展了一项前瞻性队列研究。招募了 5 至 11 岁健康儿童，他们接受了两剂 mRNA COVID-19 疫苗（BNT162b2）方案或一剂灭活（CoronaVac）疫苗后再接种 BNT162b2 疫苗方案。此外，还招募了在 1 至 3 个月前接种过两剂 BBIBP-CorV 的健康儿童，给予异源 BNT162b2 作为第三剂（加强针）。通过在线自报告问卷评估反应原性。免疫原性分析旨在确定针对野生型 SARS-CoV-2 的结合抗体。使用焦点减少中和试验检测针对奥密克戎变异体（BA.2 和 BA.5）的中和抗体。共有 166 名符合条件的儿童入组。接种疫苗后 7 天内发生的局部和全身不良事件为轻度至中度，且耐受良好。两剂 BNT162b2、CoronaVac 后序贯 BNT162b2 以及两剂 BBIBP-CorV 后序贯 BNT162b2 组诱导的抗受体结合域（RBD）IgG 水平相似。然而，两剂 BNT162b2 和两剂 BBIBP-CorV 后序贯 BNT162b2 组诱导的针对奥密克戎 BA.2 和 BA.5 变异体的中和活性高于 CoronaVac 后序贯 BNT162b2 组。CoronaVac 后序贯 BNT162b2 组对奥密克戎 BA.2 和 BA.5 变异体的中和活性较低。该组应优先接种第三剂（加强针）mRNA 疫苗。
